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Analyzing Direct Effects in Randomized Trials
with Secondary Interventions
Michael Rosenblum, Nicholas P. Jewell, Mark J. van der Laan, Stephen Shiboski,
Ariane van der Straten, and Nancy Padian
Abstract
The Methods for Improving Reproductive Health in Africa (MIRA) trial is a re-
cently completed randomized trial that investigated the effect of diaphragm and
lubricant gel use in reducing HIV infection among susceptible women. 5,045
women were randomly assigned to either the active treatment arm or not. Ad-
ditionally, all subjects in both arms received intensive condom counselling and
provision, the “gold standard” HIV prevention barrier method. There was much
lower reported condom use in the intervention arm than in the control arm, mak-
ing it difficult to answer important public health questions based solely on the
intention-to-treat analysis. We adapt an analysis technique from causal inference
to estimate the ”direct effects” of assignment to the diaphragm arm, adjusting for
condom use in an appropriate sense. Issues raised in the MIRA trial apply to other
trials of HIV prevention methods, some of which are currently being conducted
or designed.
1. Introduction
Randomized controlled trials play a critical role in the assessment of public health in-
terventions to prevent and treat disease. Standard intention-to-treat analyses, which are
straightforward comparisons of aggregate outcomes in the treatment and control groups,
are widely assumed to be the most appropriate method for analyzing and reporting trial
results. However, in intervention trials, ethical considerations generally require provision of
currently accepted disease prevention methods to all participants as a secondary interven-
tion, irrespective of study arm assignment. For example, in randomized controlled trials
of new HIV prevention methods, provision of condoms with counselling is required for all
study participants to meet human subjects protection requirements. In such cases, the stan-
dard intention-to-treat analysis may not adequately answer important questions of public
health interest. In particular, in these cases it may not address the effectiveness of the new
prevention method in the absence of the secondary intervention. Also, it may give severely
biased estimates of study product efficacy, even in blinded trials with relatively high rates of
compliance to the primary intervention (Trussell and Dominik, 2005). The situation is even
worse in unblinded trials of new HIV prevention methods; for example, in the MIRA trial
of latex diaphragms and gel, the frequency of condom use was different in the treatment
and control arms, making it quite difficult to draw conclusions about diaphragm and gel
efficacy based only on the intention-to-treat analysis (Padian et al., 2007). In this paper,
we highlight limitations in relying solely on standard analyses of randomized trials with sec-
ondary interventions such as condom counselling, and we propose a supplemental analysis
technique. Our intent is to stimulate debate on additional design and analysis approaches.
Improved methods tailored to HIV prevention trials are urgently needed, since many of
these trials are currently being conducted or planned. We focus on supplemental analy-
sis approaches throughout this paper, but briefly consider design issues in the discussion
section.
We describe a causal inference technique, called a direct effects analysis, that attempts
to isolate the effects of the secondary intervention, thereby providing more information
about primary treatment efficacy. This technique can be applied in situations where a
secondary intervention affects the primary outcome only through a measured covariate or
set of covariates. For example, in HIV prevention trials, it is thought that condom provision
and counselling affect HIV risk primarily through their impact on condom use, which is often
measured in these trials. Unlike standard time-dependent regression techniques to adjust for
time-dependent confounders, the direct effects analysis adequately handles time-dependent
confounders measured in a trial. We illustrate the benefits and limitations of our direct
effects analysis by applying it to the trial entitled “Methods for Improving Reproductive
Health in Africa” (MIRA) (Padian et al., 2007), a randomized controlled trial investigating
the effect of providing diaphragm and non-contraceptive, lubricant gel (Replens), on male-
to-female HIV transmission.
For simplicity, we consider randomized controlled trials with two arms, in which a pri-
mary intervention is provided only to the treatment arm, and a secondary intervention
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2(such as condom provision and counselling) is given to both treatment and control arms.
This design is currently used in virtually all trials that evaluate new HIV prevention meth-
ods. Examples include trials evaluating the effects of microbicides (Mantell et al., 2005),
male circumcision (Auvert et al., 2005; Bailey et al., 2007; Gray et al., 2007), and woman-
controlled barrier methods (Padian et al., 2007). In such trials, one risks overlooking and
perhaps dismissing effective new HIV prevention methods when interpretations of trial re-
sults are based solely on a standard intention-to-treat analysis. It is also possible that an
intention-to-treat analysis would overstate the benefits of an intervention, were it deployed
in a different setting than that of the study. Direct effects analyses can provide useful,
supplemental information to help identify whether a secondary intervention may be having
these effects.
We focus primarily on unblinded trials (where participants know which study arm they
are in), since here the problems in interpreting the intention-to-treat estimator can be worse
than in blinded trials. Unblinding may be a necessary part of a trial design, for example in
trials of barrier methods or male circumcision where no placebo is used; some unintended
unblinding may also occur in trials with placebo (Friedman et al., 1998). Though we
concentrate on unblinded trials with secondary interventions, such as the MIRA trial, we
also discuss analogous issues in blinded trials. In particular, we briefly describe problems in
interpreting the intention-to-treat analysis in blinded trials, and also explain how a direct
effects analysis can be applied to obtain useful information in blinded trials in the discussion
section of the paper.
Unblinding leaves open the possibility that differences in average outcomes between the
two study arms could be due to factors (such as behaviour change in response to treatment
assignment) other than efficacy of the treatment being studied. Also, with unblinding,
average outcomes that are equal in the two study arms do not rule out the treatment
being efficacious. For example, in the MIRA trial, which is unblinded, the fact that the
HIV infection rates in the two study arms were nearly identical does not necessarily mean
that latex diaphragms offer no protection against HIV; an alternative explanation, whose
plausibility we explore in this paper, is that being assigned to the diaphragm arm resulted
in significantly less condom use, which may have cancelled out a potentially protective
effect from diaphragms. A direct effects analysis aims to isolate the effect of a suspected
alternative causal pathway connecting treatment assignment to outcome, in order to help
assess whether such alternative explanations are plausible. Our approach is based on a
method of direct effects analysis from Robins and Greenland (1992) and Pearl (2000b).
This method is also discussed in Petersen et al. (2006), under a different set of assumptions.
Our paper is organized as follows: We describe the MIRA trial in Section 2. In Sec-
tion 3 we discuss the limitations of intention-to-treat analyses in the presence of secondary
interventions or unblinding. In Section 4 we introduce direct effects, and in Sections 5 and
6 we present estimators of direct effects, and the assumptions needed for these estimators
to be valid. In Section 7, we provide summary data from the MIRA trial, and then examine
the results of standard intention-to-treat analyses as well as direct effects analyses. Lastly,
in Section 8 we interpret the results of the direct effects analysis, discuss its limitations as
well as other settings where it can be applied, and then consider alternative analysis and
design approaches.
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32. The MIRA Trial
We briefly describe the MIRA trial, used throughout the paper to illustrate a direct effects
analysis and its interpretation. The MIRA trial is a randomized controlled trial with two
arms. In the “diaphragm arm,” each subject was instructed to use a fitted Ortho All
Flex diaphragm, Replens non-contraceptive, lubricant gel, and condoms at all sex acts, and
were supplied with these products. In the “control arm,” each subject was instructed to
use condoms at all sex acts, and was supplied with condoms. Additionally, in both arms,
subjects were given intensive condom counselling, as well as diagnosis and treatment of
sexually transmitted infections. The eligibility criteria for enrolment in the study included
being a woman 18-49 years old, HIV-negative at baseline, sexually active, and non-pregnant.
5,045 women were enrolled at three sites in South Africa and Zimbabwe from September
2003 until September 2005. Participants were assessed at quarterly clinic visits with a goal
of following each participant for two years. The median follow-up period was 21 months.
Before we looked at any HIV outcome data, we chose as measure of a subject’s condom
use over the period since her last visit to be the participant’s response to the question:
“Did you use a condom at your last sexual intercourse?” This choice was based in part
on a growing literature regarding accurate measures of condom use based on self-reporting
questionnaires (Anderson et al., 1998). Reported condom use at last sex, recorded at
each follow-up visit, averaged 53.5% across all visits in the diaphragm arm and 85.1% in
the control arm. (Note that other data show an increase in overall condom uptake after
recruitment in both arms–see Padian et al. (2007)).
Diaphragm use, based on self-reports of use at last sex at each clinic visit, averaged
73% in the diaphragm arm. Diaphragm use at last sex was reported at only 0.15% of visits
by participants in the control arm. For a detailed description of subject recruitment and
retention, eligibility, survey instruments and data collection, see Padian et al. (2007).
A key public health question is how much, if any, protection diaphragms provide against
male-to-female HIV infection in a community—as compared to a research—setting. Another
important question is how much protection consistent diaphragm and gel use (but no con-
dom use) provide, compared to unprotected sex. As further discussed in Section 3, neither
of these public health questions is answered adequately by a standard intention-to-treat
comparison of HIV infection rates between study arms.
3. Intention-To-Treat Analysis
The simplest intention-to-treat analysis of a randomized controlled trial compares the av-
erage outcome for the treatment group to that for the control group. For example, in the
MIRA trial, this would be a comparison of HIV incidence between the diaphragm arm and
control arm. Such an analysis may also include this comparison stratified by pre-specified
covariates measured before randomization. The advantages of an intention-to-treat analysis
in many types of randomized controlled trials include:
(a) An intention-to-treat analysis is completely protected from confounding, since it does
not involve any measurements made after randomization (e.g. adherence to treatment)
except for the outcomes of interest.
(b) An intention-to-treat analysis unequivocally answers a specific causal question via its
simplest interpretation: specifically, it estimates the effect of the primary intervention
in the study setting. We refer to the relative risk of infection between treatment and
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4control arms in a particular setting (e.g. in a community setting, in a study setting)
as the treatment “effectiveness.”
(c) An intention-to-treat analysis gives a conservative approximation of treatment efficacy.
Treatment efficacy, the effect one would observe if treatment were given in an ideal
setting where full adherence were guaranteed, is likely to be greater than the effect
measured under non-ideal conditions of the trial where there is non-compliance.
Before presenting limitations of the usefulness of the intention-to-treat estimator in the
setting of trials with secondary interventions, we briefly review the limitations with relying
solely on this estimator that have been pointed out in other settings. Sheiner et al. (1995)
point out problems in interpreting the intention-to-treat analysis under non-compliance
to assigned treatment, and argue that further analyses are needed to understand study
product effectiveness and efficacy. Frangakis and Rubin (1999) show that the intention-
to-treat estimator can be a biased estimator of product effectiveness in the presence of
non-compliance followed by missing outcomes. Hirano et al. (2000) present an example of
an unblinded randomized trial with a strongly positive intention-to-treat result, but argue
based on further analyses that this result may be more likely due to the encouragement to
take the treatment than to the treatment itself.
In prevention trials with a secondary intervention or unblinding, the advantages (b) and
(c) listed above may be of little value in answering the most important public health ques-
tions related to the primary intervention. First, the simple intention-to-treat comparison
may differ substantially from the same comparison in other populations whose members
are both subject to different information on the possible efficacy of diaphragms, and who
are not provided with free condoms coupled with intensive counselling; this type of limita-
tion of the intention-to-treat estimator has been pointed out by Feinstein (1985), Sheiner
et al. (1995) and Friedman et al. (1998). Also, while it is well known that in blinded trials,
standard intention-to-treat analyses may underestimate product efficacy (Feinstein, 1985;
Sheiner et al., 1995; Friedman et al., 1998), these analyses may be even less informative in
the presence of a secondary intervention such as condom provision and counselling (Trussell
and Dominik, 2005). This can occur, for example, when the secondary intervention dif-
ferentially affects adherers and non-adherers to the primary study product; Trussell and
Dominik (2005) gives specific examples of scenarios in which this occurs. In short, the
question definitively addressed by the standard intention-to-treat analysis may not be of
major public health interest.
Second, in unblinded trials, the intention-to-treat analysis may be severely impacted
when the primary intervention results in unintended behaviour changes. For example,
in the MIRA trial, those randomized to the diaphragm arm reported much less condom
use, as compared to the control arm. Without considering the impact of this differential
condom use, an intention-to-treat result of no difference in HIV infections between study
arms would be consistent with both (i) the diaphragm being not efficacious, but also (ii)
the diaphragm providing some protection that may have been cancelled out by additional
infections due to decreased condom use in the diaphragm arm. Unintended effects of study
arm assignment are illustrated in the causal diagram of Figure 1 which shows schematically
how the overall causal effect of study arm assignment can be viewed as having two distinct
causal pathways: (i) a direct effect of treatment on HIV infection (the top arrow), and
(ii) an indirect effect through condom use that, in turn, affects the risk of infection (the
indirect effect of treatment assignment). Causal diagrams represent sets of assumed causal
relationships: for an introduction to causal diagrams and their interpretation see Pearl
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5(2000a) or Chapter 8.2 of Jewell (2004).
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Figure 2: Direct Effects Causal Diagram
with Pre−Treatment Confounder W
PRE−TREATMENT
CONFOUNDER (W)
(R)
STUDY ARM
CONDOM
USE (C)
HIV STATUS
(I)
Figure 1: Direct Effects Causal Diagram
Figures 1 and 2
4. Direct Effects Analysis: Overview, Definitions and Causal Interpretation
Given the large difference in reported condom use between the two study arms in the MIRA
trial (53.5% in the diaphragm arm vs. 85.1% in the control arm), we would like to better
understand the role of condom use in mediating the effect of treatment assignment on HIV
outcome. For the MIRA trial, we decided to focus on condom use as a mediator for two
reasons. First, the condom provision and intensive counselling intervention was believed
primarily to affect condom use, and not to affect other HIV risk factors, and it is of major
public health interest what the effect of diaphragms would be in the absence of condom
counselling, where condom use is generally quite low. Second, except for diaphragm use,
condom use was the only time-dependent variable measured in the MIRA trial that was
meaningfully different in the two study arms. Variables such as number of other partners
and frequency of sex were measured but each showed less than a 5% difference between the
two arms.
4.1. Direct Effects Defined through Hypothetical Randomized Trials
Ideally, we would like to know what the infection rates would be in a hypothetical ran-
domized trial in which the diaphragm intervention were given to one arm, and in which
all participants were constrained never to use condoms. Such a trial is highly unethical so
cannot be conducted. In our direct effects analysis, we attempt to approximate the results
of such a trial, using data from the MIRA study. If we are successful, this would shed light
on the efficacy of diaphragms. For example, if we conclude that in this hypothetical trial
there would be no benefit of the diaphragm intervention, this would be strong evidence that
the diaphragm was not efficacious in preventing HIV infections (unless actual diaphragm
use is much lower than what subjects reported). Alternatively, if we would conclude that in
such a trial there would be a strong benefit of the diaphragm intervention, then this would
be evidence in favour of diaphragm efficacy.
We describe several hypothetical scenarios below, in which we talk about how many new
HIV infections would have occurred had all study subjects been constrained to either never
use condoms or always use condoms. It has been argued that in order for such hypothetical
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6scenarios to be well defined, it must be possible, at least in principle, to imagine interventions
that would lead to such constraints being enforced (Frangakis and Rubin, 2002). We think
the constraint on never using condoms could be approximately established by a hypothetical
(unethical) intervention. In general, without condom counselling and provision, condom use
is quite low and it is possible to imagine an intervention (that of course should never be
done) discouraging condom use that would reduce this further and not much affect HIV risk
factors in any other way. Similarly, in theory, an intervention is possible that would result
in condoms almost always being used. We argue that our estimator based on data collected
in the MIRA trial gives consistent, asymptotically normal estimates of the infection rates
in these hypothetical scenarios, under a set of strong assumptions described in Sections 5
and 6 below. The validity of these assumptions is discussed in detail in Section 8; there, we
describe significant sources of bias in our estimator, including reporting bias in condom use
and other data, and unmeasured confounders such as male partner characteristics.
Consider what the infection rate would be in the following two hypothetical scenarios:
(1) all subjects in the MIRA trial are assigned to the diaphragm arm and are constrained
to use condoms every time they have sex; (2) all subjects in the MIRA trial are assigned to
the control arm and are constrained to use condoms every time they have sex. We call the
ratio of infection rates in the two scenarios the “direct effects relative risk” of treatment
assignment with condom use fixed at “always.” The ratio of infection rates in the same
pair of hypothetical scenarios, except with all subjects constrained to never use condoms,
gives the direct effects relative risk with condom use fixed at “never.” This definition of
direct effects relative risk corresponds to Type I (“controlled”) direct effects in Petersen
et al. (2006). The main challenge in a direct effects analysis is to estimate these quantities
using data collected from a randomized trial in which subjects themselves (or their partners)
decided when to use condoms, and where condom use is not objectively measured but is
self-reported.
4.2. Direct Effects in terms of Potential Outcomes
The above definitions can be written in terms of potential outcomes. The potential outcomes
viewpoint has a long history related to work by Fisher and Neyman (as described in Angrist
et al. (1996)), and later extended by Rubin (Rubin, 1974) and Robins (Robins, 1986),
though it is not universally accepted (see e.g. Dawid (2000)). In this setting, a potential
outcome Irc is defined for each subject in the population under each of the four possible
combinations of r ∈ {0, 1}, c ∈ {0, 1}. Let r = 0 indicate the control arm, and r = 1 indicate
the diaphragm arm; similarly, c = 0 indicates never using condoms, and c = 1 indicates
always using condoms. For a given subject, Irc represents whether that subject would have
become infected with HIV had she been assigned to study arm r and been constrained to
use condoms at level c. Irc can either be 0 indicating no HIV infection, or 1 indicating HIV
infection. The direct effects analysis involves estimating the probability of HIV infection,
prc := Pr(Irc = 1) for a randomly chosen subject from the MIRA study, would she have
been assigned to arm r and simultaneously constrained to use condoms at fixed level c, for
r ∈ {0, 1} and c ∈ {0, 1}. These probabilities can then be combined to make appropriate
causal comparisons; for example, we can compute the ratio p1c/p0c to get the direct effects
relative risk of treatment for condom use fixed at level c.
We now describe how the potential outcomes {Irc} connect to the observed data in the
MIRA trial. For each study subject, the study arm assignment she received in the trial is
denoted by R, with R = 0 indicating the control arm and R = 1 indicating the diaphragm
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7arm. For the time being we assume that use of condoms is simply recorded as C = 1 for use
and C = 0 for non-use. We discuss more precisely how measurement of C was done in the
MIRA trial, and in particular how it was measured over time, in Section 6. Let I indicate
HIV status at the end of the trial, with I = 0 indicating not infected, and I = 1 indicating
infected. We emphasize the distinction between potential (generally unobserved) outcomes
Irc and the observed quantities (R, C, I) for each subject. The “consistency assumption”
connects the observed data (including R, C, I) to the set of potential outcomes {Irc}. It
states that the observed infection status I is equal to the potential outcome Irc when
observed study arm assignment R = r and observed condom use C = c. We consider the
other, unrealized potential outcomes for each subject as missing data, and apply causal
inference methodology of van der Laan and Robins (2003) accordingly.
It is important to note the asymmetry here between the two variables R and C in
that the former refers to assignment to a study arm (but not necessarily use of the study
product) and the latter refers to actual use of condoms. Thus, direct effects relative risks do
not measure, for example, effectiveness of the diaphragm intervention in a setting in which
condom use is merely encouraged; they measure effectiveness of the diaphragm intervention
in a setting in which condom use is constrained at a fixed level.
Direct effects analyses provide valuable information for understanding the efficacy of the
primary treatment. Though our direct effects relative risks are not targeted at estimating
treatment efficacy, and so give biased estimates of efficacy, they do peel away a layer of
distortion that results from using the intention-to-treat estimator as an estimate of efficacy.
The direct effects analysis removes distortion caused by both (i) the effect of treatment
assignment on HIV infection through changing condom use and (ii) the effect of a secondary
treatment on HIV infection, insofar as this is captured through changed condom use. The
direct effects estimate may give better (though still biased) estimates of efficacy than an
intention-to-treat estimator, when the effects in (i) or (ii) are strong, and the remaining
effect of treatment assignment on HIV outcome is due primarily to use of the primary
study product. The effects of (i) and (ii) are believed to be strong in the case of the MIRA
trial, and all data collected indicate that no other measured HIV risk factors (e.g. number
of partners, frequency of sex) were affected by treatment assignment. However, it is quite
possible that there are HIV risk factors affected by study arm assignment not captured by
the study data; this would result in additional bias when direct effects estimates are used
as (conservative) estimates of study product efficacy.
Direct effects analyses may also be useful in formulating prevention messages to the
community. If justified by the direct effects analysis of the MIRA trial and well supported
by evidence from other trials, it would be important to communicate, for example, that for
those using condoms consistently, diaphragms offer limited additional protection against
HIV infection, but for those never using condoms, diaphragms have an effectiveness of x%.
Alternatively, findings may indicate that assignment to diaphragms are similarly beneficial
across all levels of condom use (i.e. their benefit is additive to condoms on a multiplicative
scale, say). Such a finding would have different implications for the promotion of diaphragm
use and integration of their value into public health messages about HIV prevention.
5. Estimating Direct Effects in a Single Time Point Setting
We describe how to estimate direct effects in what we call the “single time point setting,”
for the MIRA trial. We categorize all participants, based on their self-reported condom
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8use at last sex at each of the first three visits. “Infrequent users” (C = 0) are those who
reported condom use at last sex in at most one out of the first three visits, and “frequent
users” (C = 1) are those who reported condom use at last sex in all of the first three visits.
We let I represent HIV status at the end of the trial (which consists of a total of eight
visits, though some women were not followed-up for the full eight visits). Participants who
became infected with HIV in the first three visits were not included in this single time point
analysis; even though the number of HIV infections in each arm by the end of the first three
visits was nearly identical (84 in the diaphragm arm, 81 in the control arm), excluding these
early infections still could potentially lead to bias.
A naive analysis that ignores confounding variables is subject to bias since condom use
was not constrained by the experimenters, but depends on the individual circumstances and
choices of the trial subjects. In order to obtain consistent, asymptotically normal estimates
of the direct effect of assignment to the diaphragm arm from observed data, all confounders
of the effect of condom use on HIV status must be measured. For example, a possible
confounder is number of male sex partners. This is a risk factor for HIV infection and
may influence frequency of condom use (for example, if condoms are rarely used in marital
relationships but routinely used with other partners).
Potential confounders measured in the MIRA trial can be categorized as either baseline
factors (denoted by W ) or time-dependent measurements (denoted by D). Baseline factors
measured included (i) personal characteristics (employment status, living with husband,
age, ever pregnant, HSV-2 status); (ii) regular partner’s characteristics (partner ever tested
HIV-positive, partner’s age and employment status, whether subject or her partner makes
condom use decision); (iii) sexual habits (number of lifetime male partners, frequency of
intercourse, other contraceptive use, whether had sex under influence of alcohol in past 3
months, condom use at last sex); and (iv) study site. Time-dependent confounders included
diaphragm use at last sex, sexual abstinence since last visit, HSV-2 incidence, and whether
sexual partners were known to have multiple partners during the previous three months.
In Sections 5.1 and 5.2, we describe how to estimate the HIV infection probabilities
prc = Pr(Irc = 1), for all four combinations of r ∈ {0, 1}, c ∈ {0, 1}; these estimates can then
be combined to estimate direct effects relative risks. To present the simplest case of a direct
effects analysis, in Section 5.1 we describe this analysis assuming all potential confounders
are measured before randomization. In Section 5.2, we extend the estimation techniques to
cover confounding variables that are measured post-randomization and may lie on a causal
pathway between study arm assignment and condom use. In Section 6, we deal with time-
dependent measurements, including time-dependent confounding. In all of these sections, we
present the inverse probability of treatment weighted (IPTW) estimator for the direct effects
of study arm assignment (R) on HIV status (I), with condom use “fixed” at a particular
level. In particular, we describe a set of assumptions that guarantee the IPTW estimator
will give a consistent and asymptotically normal estimate of these direct effects, and then
show how to compute the IPTW estimator. Consistency implies the estimator converges in
probability to the correct value, and asymptotic normality allows for asymptotically valid
confidence intervals. The proofs that our assumptions imply consistency and asymptotic
normality follow directly from arguments in van der Laan and Robins (2003). For all of
the discussion below, we assume that the data observed on each subject can be viewed as
random draw from a hypothetical, infinite population of subjects.
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95.1. Estimation of Direct Effects When All Confounders Can Be Measured Prior to Ran-
domization
We consider the case in which all confounders of the effect of condom use on HIV sta-
tus are measured before study arm assignment. Such a setting is depicted in Figure 2 of
Section 3 above, in which the variable W denotes pre-treatment (baseline) confounders.
The proposed estimator of prc is an example of the class of inverse probability of treat-
ment weighted (IPTW) estimators described in Robins and Finkelstein (2000). The IPTW
estimator requires a correctly specified model for the probability of condom use C, given
baseline confounders W and study arm assignment R. In Section 6 we explain why we chose
to use the IPTW estimator instead of other possible estimators (including G-computation
estimators (Robins, 1986), doubly robust estimators (van der Laan and Robins, 2003), and
targeted maximum likelihood estimators (van der Laan and Rubin, 2006)).
Before presenting the IPTW estimator, we state assumptions under which it gives con-
sistent, asymptotically normal estimates of the direct effects relative risks. First, we make
the following conditional independence assumption, sometimes referred to as the “random-
ization assumption” (van der Laan and Robins, 2003),
C ⊥ {Irc}|W, R. (1)
That is, condom use C is independent of the potential outcomes {Irc}, conditional on
baseline confounders W and study arm assignment R. Intuitively, this means that, within
strata having the same study arm R and the same baseline measurements W , the decision
to use condoms is not an indicator of underlying HIV risk (e.g. due to having high-risk
partners, many partners, or having other STIs). This assumption implies that there are no
unmeasured confounders of condom use and HIV infection.
We make the following assumption, called the experimental treatment assignment (ETA)
assumption: For all r, c, w, Pr(C = c|R = r, W = w) > 0. That is, no stratum of treatment
assignment and baseline confounders precludes the possibility of using condoms at any
specific level. If this assumption is false, direct effects will not be identifiable from the
data alone, unless further model assumptions are made. We also make the consistency
assumption introduced in Section 4.2.
We can connect the probabilities of specific potential outcomes that we ultimately care
about to quantities that can be estimated from the observed data using the following chain
of equalities:
Pr(Irc = 1) =
∑
w
Pr(Irc = 1|W = w)Pr(W = w)
=
∑
w
Pr(Irc = 1|W = w, R = r, C = c)Pr(W = w)
=
∑
w
Pr(I = 1|W = w, R = r, C = c)Pr(W = w)
=
∑
w
Pr(I = 1, R = r, C = c, W = w)
Pr(R = r|W = w)Pr(C = c|W = w, R = r)
. (2)
The second equality follows from Assumption (1) and the fact that R is randomized (so
R ⊥ {Irc}|W ); the third equality follows from the consistency assumption described in
Section 4 above; and the last equality follows by basic rules of probability. The experimental
treatment assignment (ETA) assumption insures that all the terms in (2) are well-defined.
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Note that once we get estimates for the left hand side of this equation, for all values of r, c,
we can estimate the direct effects relative risks Pr(I1c = 1)/Pr(I0c = 1) for each level of
fixed condom use c. We also point out that estimating Pr(Irc = 1) using (2) is equivalent
to solving the following estimating equation:
E
(
1
Pr(R|W )Pr(C|W, R)
(I −m(R, C|β))
)
= 0, (3)
where m(r, c|β) denotes a saturated (non-parametric) model for the unknown probability
Pr(Irc = 1).
To estimate (2), we first estimate its numerator using the empirical distribution of the
data. The first term in the denominator of (2), Pr(R = r|W = w), equals 1/2 since R
was randomized. The second term in the denominator can be estimated by the empirical
distribution if W is low-dimensional, or using a logistic regression model, for example, if W
is high-dimensional. Substituting such estimates for the quantities in the right hand side of
(2), and summing over w, we get what is referred to as the inverse probability of treatment
weighted (IPTW) estimator for Pr(Irc = 1). We use the bootstrap, as described in Efron
and Tibshirani (1993), to generate confidence intervals for direct effects relative risks based
on these estimators. Alternatively, the influence curve for the estimator could be used for
statistical inference, as described in van der Laan and Robins (2003).
The argument above assumed that all confounders were measured at baseline, prior to
randomization. In the next section, we treat the case in which there are confounders of
condom use and HIV status that are themselves affected by study arm assignment.
(R)
STUDY ARM
CONDOM USE
(C)
HIV STATUS
(I)
CAUSAL
INTERMEDIATE (D)
Figure 3: Direct Effects Diagram with Confounder as Causal Intermediate
5.2. Estimation of Direct Effects With Confounding by Causal Intermediates
In the MIRA trial, there are potential confounders of condom use and HIV status that
are themselves affected by study arm assignment. Such confounders are called “causal
intermediates,” and are denoted by D. This situation is illustrated in the causal diagram
of Figure 3, where for clarity, pre-randomization potential confounders W are not shown.
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For an example of a potential confounder that may be a causal intermediate, consider
diaphragm use, defined similarly to condom use for the single time point case above–that
is, diaphragm use is a dichotomized summary measure, based on self-reports of use at last
sex at the initial three visits. Diaphragm use may affect the decision to use condoms and it
also may affect HIV infection (by possibly acting as a physical barrier); thus, diaphragm use
may be a confounder that is a causal intermediate. In general, the set of confounders that
are causal intermediates will be a vector D including more variables than just diaphragm
use (e.g. frequency of sex, number of partners). For concreteness in our explanations, we
assume diaphragm use is the only confounder that is a causal intermediate; however in our
statistical analyses, we included all the time-dependent variables listed in Section 5. Note
that diaphragm use will be “never” (D = 0) for virtually all participants in the control arm,
except the few who obtained and used diaphragms on their own.
A single regression (e.g. regressing I on R, D, C) cannot be used to estimate the direct
effects of R on I , fixing C, in the presence of confounding by causal intermediate D as in
Figure 3 (Rosenbaum, 1984; Robins, 1997; Hernan et al., 2000; Petersen et al., 2006). The
problem is that if one controls for such a causal intermediate in the regression analysis, one
blocks a causal pathway of interest; in the above diagram, by controlling for diaphragm use
D, one would block the causal pathway from study arm R through diaphragm use D to HIV
status I , which is an important part of what we are trying to estimate. Alternatively, by not
controlling for such a causal intermediate, one’s estimates may be biased due to confounding
from the causal intermediate. The analysis we outline below adequately handles confounding
by measured causal intermediates.
In the presence of confounding by causal intermediates, the randomization assumption
analogous to assumption (1) of Section 5.1 is more complicated. It involves not only po-
tential HIV outcomes Irc under different scenarios for study arm assignment r and condom
use c, but also potential outcomes for diaphragm use under different possible study arm
assignments. We let Dr represent what an individual’s diaphragm use would be, would she
have been assigned to study arm r. The randomization assumption analogous to (1) now
takes the form,
C ⊥ {Irc, Dr}|W, R, D. (4)
Intuitively, given knowledge of a subject’s baseline measurements W , study arm assignment
R, and diaphragm use D, her observed condom use gives no additional information as to
either (1) her risk of HIV infection would she have been assigned to arm r and would she
have used condoms at fixed level c or (2) her diaphragm use were she assigned to the other
study arm R = r.
In the case here of confounding by causal intermediates, the experimental treatment
assignment assumption is that for each possible w, r, c, d, we have Pr(C = c|R = r, D =
d, W = w) > 0. That is, no strata of treatment assignment, diaphragm use, and baseline
confounders precludes the possibility of using condoms at any specific level. The consistency
assumption in this setting connects the observed data (including W, R, D, C, I) to the set of
potential outcomes {Irc, Dr}. It states that the observed diaphragm use D is equal to the
potential outcome Dr when R = r; furthermore, it states that infection status I is equal
to the potential outcome Irc when observed study arm assignment R = r and observed
condom use C = c.
Analogous to the derivation in Section 5.1, the assumption (4), the consistency assump-
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tion, and the experimental treatment assignment assumption imply:
Pr(Irc = 1) =
∑
w,d
Pr(I = 1, R = r, C = c, D = d, W = w)
Pr(R = r|W = w)Pr(C = c|W = w, R = r, D = d)
(5)
Estimating Pr(Irc = 1) using (5) is equivalent to solving the following estimating equation:
E
(
1
Pr(R|W )Pr(C|W, R, D)
(I −m(R, C|β))
)
= 0 (6)
where m(r, c|β) denotes a saturated (non-parametric) model for the unknown probability
Pr(Irc = 1).
Here, as in Section 5.1, we estimate the numerator in the right hand side of Equation 5 by
the empirical distribution of the data, and the denominator by fitting a logistic regression
model for Pr(C = c|W = w, R = r, D = d). We again use the bootstrap to generate
confidence intervals for such estimates.
6. Time-dependent analysis
We have so far discussed estimating direct effects only in the single time point scenario,
in which baseline covariates W are measured, followed by assignment to a study arm R,
followed by further measurements D and C, and lastly outcome I is measured. One striking
disadvantage of this simple approach is that the intermediate variable condom use is based
on a single summary whereas actual condom use varies over time. This is also the case
for measures of diaphragm use as a confounding variable of condom use as discussed in
Section 5.2. In this section, we extend the IPTW estimators of Section 5 to provide a
time-dependent analysis of direct effects, again using the MIRA trial as an illustration.
The description below is an application of the estimation methodology for causal inference
based on longitudinal data given in Section 6.4 of van der Laan and Robins (2003). Note
that a single time-dependent regression equation adjusting for causal intermediates would
suffer from the problem of confounding by causal intermediates discussed is Section 5.2 at
every time point. The analysis presented in this section adequately deals with measured,
time-dependent confounders.
In this section, we first describe why we chose to use the IPTW estimator to estimate
direct effects in the MIRA trial. Then we describe exactly what time-dependent observations
are made for each subject in the MIRA trial. Next, we link the observed data to potential
outcomes. In terms of these potential outcomes, we present the main assumptions needed
for our estimator to give a consistent estimate of the effect of study arm assignment on HIV
infection, for fixed patterns of condom use over time. We then present a model for the hazard
of HIV infection at each visit, capitalizing on information about the time lag between HIV
infection and when antibodies are detectable. Finally, we give the proposed direct effects
estimators with brief details about implementation. Due to limitations on space, we omit
the details of how sexual abstinence between quarterly visits was incorporated into our
models; full details are given in our technical report (Rosenblum et al., 2007) available
online at the web-address given in the bibliography.
6.1. Why We Chose the Inverse Probability of Treatment Weighted (IPTW) Estimator
We chose to use the IPTW estimator rather than other possible estimators (including G-
computation estimators (Robins, 1986), doubly robust estimators (van der Laan and Robins,
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2003), and targeted maximum likelihood estimators (van der Laan and Rubin, 2006)). The
decision of which estimator is most appropriate for a given data analysis requires knowledge
of which parts of the data generating distribution can most reliably be modelled and esti-
mated from the available data. Our decision to use the IPTW estimator was based on the
fact that it only requires correct specification of models for the probability of condom use at
visit v, given observed covariates at or before visit v. In contrast, the G-computation esti-
mator would require correct models for the probability of HIV infection given past covariates
and, at each visit v, models for the joint probability of all time-dependent confounders mea-
sured at visit v given past covariates. The doubly robust estimator and targeted maximum
likelihood estimator would require models for all of the aforementioned probabilities (but
are robust to incorrect specification of some of these models).
In consultation with the investigators in the MIRA trial, we decided that the models
required for the IPTW estimator could be more reliably specified and estimated than the
other models mentioned above. One reason is that in our data, among individuals with a
given covariate history, there often are many subject-visits at which condoms were used, as
well as many subject-visits where condoms were not used; this provided adequate data for
estimating the probability of condom use given covariate history. In contrast, HIV infections
were relatively rare, as were some values of time-dependent confounders (such as having
multiple partners), so data for estimating their probabilities was sparse.
6.2. Observed Data
At enrolment, each subject’s baseline covariates W (as listed in Section 5) were measured,
prior to study arm assignment. At each of up to 8 follow-up visits, time-dependent con-
founders (as listed in Section 5), condom use at last sex, and HIV status were recorded;
for follow-up visit v (where v = 0 refers to enrolment), let D(v) and C(v) denote the val-
ues of the time-dependent confounders, and condom use at last sex, respectively. Though
in our analyses, D(v) is a vector containing all the measured time-dependent confounders
(including diaphragm use), we will refer to it below as “diaphragm use at visit v” in order
to simplify our exposition. Measurement of HIV infection status at visit v is denoted by
I(v). Ignoring missing data for the moment, data collected on a single participant from
enrolment (v = 0) through the last follow-up visit (v = 8) is then represented as:
O = (W, R, D(0), C(0), I(0), D(1), C(1), I(1), . . . , D(8), C(8), I(8)) . (7)
Based on this data, the goal is estimation of the effect of study arm assignment on the
hazard of HIV infection, under fixed patterns of condom use over time.
The time-ordering implied by our representation (7) of each participant’s data, that
baseline confounders W precede randomization R, which precedes decision to use diaphragm
at last sex before visit 0, etc., have important consequences. If these variables do not actually
occur in this order, our analysis will be biased. For example, if a participant’s decision to
use a diaphragm at last sex before visit 1 (represented by D(1)) occurred after the decision
to use a condom (represented by C(1)), then our ordering would be incorrect leading to
bias in our estimator. Our assumption that the decision to use a diaphragm at a given
sex act precedes the decision to use a condom is based on the fact that the diaphragm
can be inserted up to 24 hours prior to sex, while a condom must be put on immediately
before sex; however, this is no guarantee that our assumption is correct. As a sensitivity
analysis to our choice of time-ordering, we also ran our direct effect analyses using a time-
ordering in which C(i) precedes D(i), and got nearly identical results to the analysis using
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the time-ordering (7). However, in reality the decision to use condoms and/or diaphragms
will be more complex; whether such a decision is adequately captured by our time ordering
assumption is, unfortunately, not testable from the data collected.
Also, we need to lag all measurements except our HIV status measure by one visit, since
HIV infection is detectable by the tests used in the study within a 3 month window, and
usually takes at least 3 weeks to be detectable. Though this lag was included in our data
analyses, we omit it in explanations of our estimator below for clarity.
We represent the set of observations of condom use over all visits C(0), C(1), . . . , C(8)
by the more compact notation C¯, and similarly for D¯ and I¯ . We use the notational
convention that the first k components of a vector A¯ is represented by A¯(k); that is,
A¯(k) = (A(1), . . . , A(k)). We denote the vector of length 8 of all 0’s by 0¯, and the cor-
responding vector of all 1’s by 1¯.
6.3. Potential Outcomes
As done for the single time point case in Section 4.2, we define direct effects in terms of
potential outcomes. For each possible combination of fixed treatment assignment, r, and
condom use over time c¯, we let Irc¯(v) represent whether a subject would be HIV-infected by
visit v were her study arm and condom use constrained to r and c¯, respectively. Similarly,
we define Drc¯(v) to represent the potential outcome for diaphragm use that would be
reported at visit v, had a subject been assigned to study arm r and had her condom use
been constrained to c¯.
We can formulate the parameters we would like to estimate in terms of potential out-
comes. We want to estimate the probabilities of HIV infection by the end of the trial, for
each study arm, in the following two scenarios: (1) were all subjects constrained to never
use condoms at last sex before each quarterly visit and (2) were all subjects constrained to
always use condoms at last sex before each quarterly visit. In terms of the above notation
for potential outcomes, these probabilities of HIV infection are prc¯ := Pr(Irc¯(8) = 1) for
r ∈ {0, 1} and c¯ ∈ {0¯, 1¯}. We can use estimates of these probabilities to compute estimates
for direct effects relative risks by taking the appropriate ratios, as described in Section 6.6.
6.4. Main Assumptions: Consistency, No Unmeasured Confounders and ETA
We make the following assumptions, which together imply that our direct effects estimator
will be consistent and asymptotically normal. First, the consistency assumption is that at
each visit v, (1) observed infection status I(v) equals the potential outcome Irc¯(v) whenever
a subject’s arm assignment R = r and condom use over time C¯ = c¯ and (2) observed
diaphragm use D(v) equals the potential outcome Drc¯(v) whenever R = r and C¯ = c¯.
Second, we assume that there are no unmeasured confounders of the relationship between
condom use and HIV infection over the visits v. More precisely, we assume at each visit
v that condom use at last sex is independent of the set of potential outcomes at all visits,
conditioned on all observations made before visit v and also on diaphragm use at visit v:
C(v) ⊥ {Irc¯, Drc¯}|W, R, D¯(v), C¯(v − 1), I¯(v − 1). (8)
We include diaphragm use at visit v in our set of observations that precede condom use
at visit v since we think diaphragm use is determined before condom use, as discussed in
Section 6.2 above. (8) is a generalization of the assumptions (1) and (4) from the single
time point case.
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Third, we make the so-called experimental treatment assignment (ETA) assumption that
the probabilities Pr
(
C(v) = 1|W, R, D¯(v), C¯(v − 1), I¯(v − 1)
)
do not equal 0 or 1, almost
surely, for any values of W, R, D¯(v), C¯(v − 1), I¯(v − 1).
Finally, we make a time-ordering assumption for our potential outcomes. This assump-
tion is that for each visit v, the potential outcomes for that visit do not depend on the
constraints, in term of condom use, that will be imposed at future visits. Formally, the
assumption is that for each visit v, the potential outcomes for that visit (Irc¯(v) and Drc¯(v))
only depend on r and c¯(v), and not on c(v + 1), . . . , c(8).
6.5. Model for the Hazard of HIV Infection
Some type of modelling is necessary to avoid extremely high variance in our estimator of the
direct effects of treatment assignment fixing condom use at “never.” This is due to there
being only 488 subjects who reported not using condoms at last sex, at all visits. Assuming
a model, as we do below, will lead to some bias due to model misspecification. However, we
are able to take advantage of important subject matter knowledge in creating the model;
in particular, our model incorporates the known time lag between when an infection occurs
and when it is detectable.
We model the hazard of HIV infection for a participant measured at visit v, would she
have been randomized to arm r and been constrained to use condoms according to c¯(v).
The model is a function of visit number v, treatment assignment r and condom use history
c¯(v).
Model for Hazard of HIV Infection:
Pr(Irc¯(v) = 1|Irc¯(v − 1) = 0) = m(v, r, c¯(v)|β0), for all v, r, c¯(v), (9)
where β0 is an unknown, time-invariant, population parameter vector. This is an example
of a marginal structural model (Robins, 1998).
In our particular choice for a low-dimensional model m, we exploit the following in-
formation about the test for HIV infection: HIV infection will, with high probability, be
detectable within a 3 month window, and usually takes at least 3 weeks to be detectable.
Therefore, (1) condom use measured at the current visit should not have an effect on the
outcome of the HIV test at that visit and (2) condom use in the previous 3 months may
have a large effect on whether HIV is detected at a given visit, compared to condom use
farther in the past. Condom use in the past cannot be completely ignored, since it may
impact future behaviour, such as future diaphragm use. We incorporated (1) and (2) into
the model by collapsing information about an entire condom use history into just the most
recent reported condom use and a single number giving the average condom use before this.
We let H(v, r, c¯(v)) denote the column vector of basis functions used in the model m in (9);
this, and the precise details of the model we used in our analyses is given in our technical
report Rosenblum et al. (2007), where we work with a slightly different model than above
that incorporates sexual abstinence between visits as well as study sites.
Once we estimate the parameter β0, as described below, we can use it to estimate
the probabilities prc¯ using the product integral (Andersen et al., 1993) for calculating the
cumulative survival probability from discrete hazards:
prc¯ = Pr(Irc¯(8) = 1) = 1−
8∏
v=1
{1−m(v, r, c¯(v)|β0)} . (10)
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6.6. Direct Effects Estimator in the Time-Dependent Setting
In this section, we present the estimating equation for the time-dependent setting that
we use to estimate the parameter β0 of the model in (9), which is then used to estimate
direct effects relative risks. The estimating equation uses “stabilized inverse probability
of treatment weights (IPTW),” (which we refer to more concisely as “stabilized weights”),
which are a generalization of standard inverse probability of treatment weights. In our
estimating equation, individual subjects contribute information for all visits except those
occurring after HIV seroconversion.
It turns out that solving this estimating equation is equivalent to solving a weighted
logistic regression, which can be done with standard statistical software. The details of
how to solve this type of estimating equation using weighted logistic regression are given in
Section 6.4 of van der Laan and Robins (2003).
Before giving the estimating equation used to estimate β0, we describe the stabilizing
weights that will be used in this estimating equation. First, consider what the standard
(non-stabilized) inverse probability of treatment weights would be in the time-dependent
setting. For each visit v, the standard IPTW weight involves the product over all visits at
and before v of the probability of observed condom use given all observed past covariates
(as well as a term for the probability of study arm assignment given baseline covariates):
1/

Pr(R|W )
∏
v′≤v
Pr
(
C(v′)|W, R, D¯(v′), C¯(v′ − 1), I¯(v′ − 1)
)

 .
Note that the IPTW weights used for the single time point estimating equations (3) and
(6) in Sections 5.1 and 5.2 are special cases (with v = 1) of this general formula.
Stabilized weights are a modification of the standard IPTW weights. Stabilized weights
include a numerator term that can only depend on the treatments R and C¯ (and so not
on D¯). They are called “stabilized” since the hope is that for large values of the standard
IPTW weights, which correspond to small values in the denominator, the numerator terms
will be small; in this case, one would prevent single observations from having a dispropor-
tionate amount of weight in the estimation procedure. The stabilized weights are similar
to the standard IPTW weights given above, except they have the following function in the
numerator, for each visit v:
Pr(R)
∏
v′≤v
Pr
(
C(v′)|R, C¯(v′ − 1), I(v′ − 1) = 0
)
.
Thus, the stabilized weights are defined as
sw
(
W, R, D¯(v), C¯(v − 1), I¯(v − 1)
)
=
∏
v′≤v Pr
(
C(v′)|R, C¯(v′ − 1), I(v′ − 1) = 0
)
∏
v′≤v Pr
(
C(v′)|W, R, D¯(v′), C¯(v′ − 1), I¯(v′ − 1)
) .
(11)
Note that by randomization, Pr(R|W ) = Pr(R) = 1/2, which cancelled out in the numerator
and denominator above.
Just as in Sections 5.1 and 5.2, we use logistic regression models to estimate the IPTW
weights. We estimate each term in the product in the numerator of (11) by fitting a separate
logistic regression model; we do the same for each term in the product in the denominator.
In deciding which variables to use in these logistic regressions models, we use the assumption
that condom use at visit v is more influenced by variables measured at the previous visit
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than by variables measured further in the past. This model assumption is incorporated
into the logistic regression models by including all variables measured in the past visit, but
only summary measures of the variables measured at earlier visits. A model assumption we
made is that no stabilized weight is larger than 25, which we incorporated by truncating
all estimated stabilized weights at 25; this assumption, qualitatively, is that there are no
sets of covariates for which the probability of condom use at last sex is very close to 0 or
to 1. We give the precise details of these logistic regression models in our technical report
Rosenblum et al. (2007).
Let Oi denote the entire set of data collected on the ith subject enrolled in the study,
and let n denote the number of subjects in the study. Recall that H(v, r, c¯(v)) denotes
the column vector of basis functions used in the model m in (9). The estimating equation
corresponding to the IPTW estimator with stabilized weights is given by
n∑
i=1
li∑
v
sw
(
W, R, D¯(v), C¯(v − 1), I¯(v − 1)
) {
I(v) −m(v, R, C¯(v)|β0)
}
H(v, R, C¯(v)) = 0,
where the inner sum for each subject i is taken starting at follow-up visit v = 1 up to
and including the first visit at which the participant tests positive for HIV, denoted by li;
for those women who remain HIV negative throughout, the sum is over all eight follow-up
visits; that is, li = 8 for these women. Note the similarity in form to the simpler estimating
equations (3) and (6). Details and proof that this estimating equation indeed has mean 0
at the true β under the assumptions given in Sections 6.2-6.5 are given in Section 6.4 of
van der Laan and Robins (2003).
Once we obtain a solution βˆ to the above estimating equation, we can use it to generate
estimates pˆrc¯ for the probability of HIV infection by the end of the trial for a randomly
chosen subject in the study, would she have been assigned to study arm r and have had
condom use profile set to c¯. Following (10) above, we have
pˆrc¯ = 1−
8∏
v=1
(
1−m(v, r, c¯(v)|βˆ)
)
We can then construct estimates of direct effects relative risks by taking ratios of the
estimates pˆrc¯. The direct effects relative risk estimate with condom use fixed at “never” is
pˆ10¯/pˆ00¯. (Recall that 0¯ denotes the vector of length 8 of all 0’s.) The direct direct effects
relative risk estimate with condom use fixed at “always” is pˆ11¯/pˆ01¯. We point out that the
estimators in Sections 5.1 and 5.2 differ from the estimator for the time-dependent case
described in this section in that the former do not assume a model on potential outcomes.
Here, we assumed the model m in (9), to deal with the high-dimensional nature of the
time-dependent data.
We used the bootstrap percentile method for constructing confidence intervals for these
direct effects relative risk estimates, where replicates were selected using subjects (not
subject-visits) as the experimental unit.
7. Results of Our Data Analyses for the MIRA Trial
In this section, we give summary statistics for the MIRA trial and then the results of the
time-dependent analysis. Due to space constraints, we don’t give the results of the single
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time point analysis, but we do discuss below how they are qualitatively similar to the results
for the time-dependent case.
Table 1 below gives the distribution of the two arms of the study with regard to the
number of seroconversions to HIV during follow-up. The intention-to-treat relative risk
of HIV infection by the end of the trial is 158/151 = 1.05 (95% CI: 0.84,1.30). 6% of
participants in the diaphragm arm and 5% of the participants in the control arm were lost
to follow-up.
The time-dependent direct effects analysis was based on a discrete time scale made up of
the eight quarterly visits by each participant, in addition to an initial enrolment visit (visit
0). For individuals who seroconverted, the (discrete) time to seroconversion was defined as
the visit number at the time of the first positive HIV test. For participants who missed
one or more visits between the last negative and first positive test, the seroconversion time
was defined as the visit number covering the midpoint between the two discordant tests.
Covariates were imputed by carrying forward the most recently observed value; for example,
if a subject came to visit 3 but missed visits 4 and 5, her covariates for visits 4 and 5 were
imputed to be what was recorded at visit 3.
Before calculating the direct effects relative risks of study arm assignment on HIV infec-
tion with condom use fixed, we looked at whether the MIRA trial data were consistent with
reported condom use being causally related to HIV infections. If it were not, then a direct
effects analysis fixing reported condom use would probably not be of much use. We did a
causal analysis of the effect of condom use at last sex on subsequent HIV seroconversion,
within each study arm separately. We did this by estimating prc¯ for r ∈ {0, 1}, c¯ ∈ {0¯, 1¯}
as described in Section 6. But instead of looking at the direct effects relative risks hold-
ing condom use fixed as described in that section, we looked at the following relative risk:
prc¯/prc¯′ , first for r = 0, c¯ = 1¯, c¯
′ = 0¯, which is the relative risk of HIV infection compar-
ing always to never condom use in the control arm. We then calculated this relative risk
prc¯/prc¯′ , except setting r = 1, c¯ = 1¯, c¯
′ = 0¯, which gives the relative risk for the diaphragm
arm. The estimates for these measures of condom efficacy are: 0.33 (95% CI 0.16, 2.33)
for the control arm and 0.54 (95% CI: 0.30, 0.98) for the diaphragm arm, indicating a sta-
tistically significant protective effect in the diaphragm arm but no statistically significant
result in the control arm; here, confidence intervals were calculated using non-parametric
bootstrap percentile method. One reason for the larger confidence intervals in the control
arm is that there were fewer instances of non-condom use in this arm, so the denominator
of the relative risk was more variable. The relative protection corresponding to the point
estimate for each arm is 1 − 0.33 = 67% for the control arm and 1 − 0.54 = 46% for the
diaphragm arm. This protection against HIV infection is less than the approximately 80%
relative protection normally ascribed to condom use (Weller and Davis-Beaty, 2002). The
lower protection reflected in the above estimates may be due to overreporting of condom use
due to social desirability bias, which would dilute the measured effectiveness of condoms.
Consider the following set of facts: (i) infection rates are similar in the two arms, (ii)
reported condom use is much lower in the diaphragm arm compared to the control arm,
and (iii) the data is consistent with condom use at last sex (as measured by self-report)
protecting against HIV infection. Together, these facts seem to suggest that the direct effect
of assignment to the diaphragm arm that is not mediated through condom use patterns,
may turn out to be positive.
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Table 1. SUMMARY OF HIV SEROCONVERSIONS BY STUDY ARM
Number of Seroconversions Woman-years Incidence Rate
Participants (percent of group) of Follow-up (per 100 woman-years)
Total 4948 309 (6.2%) 7702 4.0
Intervention 2472 158 (6.4%) 3835 4.1
Control 2476 151 (6.1%) 3867 3.9
Table 2. ESTIMATES OF THE DIRECT EFFECT OF ASSIGNMENT TO STUDY ARM ON HIV INFECTION
USING A TIME-DEPENDENT ANALYSIS, FOR CONDOM USE SET TO “NO” FOR ALL VISITS
Relative Risk of HIV Infection 95% CI Cumulative Survival Difference 95% CI
by Visit 8 through Visit 8
0.59 (0.26, 4.56) 0.10 (-0.13, 0.33)
Table 3. ESTIMATES OF THE DIRECT EFFECT OF ASSIGNMENT TO STUDY ARM ON HIV INFECTION
USING A TIME-DEPENDENT ANALYSIS, FOR CONDOM USE SET TO “YES” FOR ALL VISITS
Relative Risk of HIV Infection 95% CI Cumulative Survival Difference 95% CI
by Visit 8 through Visit 8
0.96 (0.59, 1.45) 0.00 (-0.03, 0.04)
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We now present the results of the time-dependent direct effects analysis described in
Section 6. The list of baseline and time-dependent confounders included in the analyses are
those listed in Section 5. Using the methods from Section 6, we can generate an estimate
of prc¯ := Pr(Irc¯ = 1) for r = 0, 1 and any specific pattern of condom use reported over the
8 possible visits, which is denoted by c¯. Here we focus on two extreme patterns of condom
use: (i) condoms used at last sex at all visits, so that c(v) = 1 for all v, and (ii) condoms
not used at last sex at all visits, so that c(v) = 0 for all v. The methods can be used to
estimate the direct effects for other condom use patterns as well.
Tables 2 and 3 give the results for these two extreme patterns of condom use. Table 2
gives the estimated direct effects of assignment to the diaphragm arm vs. control arm, for
condom use set to “no” at all 8 visits. First, the direct effects relative risk 0.59(95% CI:
0.26, 4.56) is given; this is an estimate of p1c¯/p0c¯ for c¯ = 0¯. We also give the direct effects
cumulative survival difference 0.10(95% CI:−0.13, 0.33), which is an estimate of (1− p1c¯)−
(1−p0c¯) for c¯ = 0¯. Table 3 gives the estimated direct effect of assignment to the diaphragm
arm vs. control arm, for condom use set to “yes” at all 8 visits, using the same format
as Table 2. All confidence intervals were calculated with the non-parametric bootstrap
percentile method, using 10,000 iterations. These results are qualitatively similar to the
results for the single time point analysis (given in our technical report (Rosenblum et al.,
2007)), in that none of them are statistically significant, and all estimates have very wide
confidence intervals.
Though both point estimates are in the direction of assignment to the diaphragm arm
being protective in these scenarios, neither is close to statistical significance. Also, based
on the bootstrap estimates of standard errors, both of the direct effects relative risk point
estimates are within one standard error of the value corresponding to no effect of assignment
to the diaphragm arm. We therefore conclude that the direct effects analysis provides no
evidence in support of, nor in refutation of, diaphragms providing a protective effect against
HIV infection.
As a sensitivity analysis to determine if the large confidence intervals in Tables 2 and 3
were a result of our stabilized weights, we ran our time-dependent analysis with no weights
at all (that is, all weights = 1). The confidence intervals were still quite large; for example,
the 95% confidence intervals for the direct effects relative risks were (0.348, 2.12) for condom
use set to “never” and (0.55, 1.18) for condom use set to “always.” We conclude that that
the large confidence intervals are not due primarily to the stabilized weights we used.
8. Discussion
The analysis above, due to large confidence intervals, does not provide information as to
whether provision of latex diaphragms and gel is protective against HIV, at fixed levels of
condom use. At first glance, this seems irreconcilable with the following facts: (i) infection
rates are similar in the two arms, (ii) reported condom use is much lower in the diaphragm
arm compared to the control arm, and (iii) the data is consistent with condom use at last sex
(as measured by self-report) protecting against HIV infection. However, the direct effects
analysis and these facts are perfectly consistent with each other; the illusory contradiction
disappears once we consider more closely how many infections may be attributed to the
observed difference in condom use, compared to the difference in HIV infections between
arms required to achieve statistical significance in a trial of this size.
We present a simple, crude adjustment for the differential reported condom use of 53.5%
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in the diaphragm arm and 85% in the control arm. We emphasize that this crude analysis
is highly susceptible to confounding (which is why we did the direct effects analysis), but
it sheds light on the apparent contradiction in the previous paragraph. We estimate, quite
roughly, the number of infections that would have been prevented had condom use been
increased in the diaphragm arm to the level observed in the control arm. That is, we
estimate the number of infections that would have been prevented, had an additional (85%
- 53.5%) = 31.6% of the 2472 subjects in the diaphragm arm used condoms consistently;
31.6% of 2472 subjects is about 781 subjects. First, we calculate how many infections we
would expect among 781 randomly chosen subjects among those in the diaphragm arm who
never used condoms. Based on the observed infection rate in the diaphragm arm among
subject-visits in which women reported no condom use at last sex (4.2% new infections
per woman-year), and the mean length of time subjects were followed-up (1.6 years), we
would expect (781 × 1.6) woman-years × 4.2% new infections per woman-year ≈ 51 of
these 781 subjects to become infected with HIV by the end of the trial. Next, we estimate
how many of these 51 infections would have been prevented had these 51 subjects instead
used condoms consistently. Assuming that reported condom use offers (100% - 54%) = 46%
protection against HIV infection, as was estimated from the data in the diaphragm arm and
explained in Section 7 above, a crude estimate of the number of infections that would have
been prevented is 46% of 51 ≈ 23 infections prevented. However, this is much lower than
the number of prevented infections required to achieve a statistically significant difference
between the two study arms, at significance level α = 0.05 (two-tailed); given that there
were 151 infections in the control arm and 158 infections in the diaphragm arm, the required
difference in infections is 39. Thus, based on this crude analysis, adjusting for the number
of infections attributed to the observed difference in reported condom use between arms
does not lead to a statistically significant difference in infections between the arms. The
direct effects analysis can be viewed as an attempt to more carefully carry out the above
crude analysis, adequately dealing with confounders and the time-dependent nature of the
data.
The direct effects estimator we used, based on the inverse probability of treatment
weighted (IPTW) estimator, could be biased if (1) there are unmeasured confounders (e.g.
characteristics of male partners associated with their condom use and HIV status); (2) there
is measurement error in reported condom use (for example, due to social desirability bias,
or if quarterly reported condom use at last sex is not sufficiently informative about overall
condom use) or measurement error in confounders; (3) the models for condom use or hazard
of HIV infection are not correctly specified; (4) missing data values are very different from
observed values; (5) the experimental treatment assignment assumption is violated (see
Section 6.4); or (6) the consistency assumption or time-ordering assumption is violated. All
of these biases may exist to some degree, with (1) and (2) being of particular concern in
the context of the MIRA trial. (1) is important since partners, who are believed to control
condom use much of the time, may be associated with important unmeasured confounding.
(2) is important since condom use by self-report is likely to be inflated upward, and this is
consistent with our causal analysis of condom use in Section 7. We treat the point estimates
for direct effects relative risks with a good deal of scepticism for these reasons.
However, the wide confidence intervals in the direct effects analysis allow us to make
the following valuable conclusion: The data in the MIRA trial do not contain enough
information to determine whether differential condom use may have masked a possibly
protective effect of study arm assignment on HIV infection. This was not evident from a
first look at the intention-to-treat results and the large difference in reported condom use,
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which on their face seemed, to the contrary, to imply that there might be enough information
in the MIRA trial data to adjust for condom use and show a positive effect of diaphragms.
The crude analysis at the beginning of this section does not account for confounding or the
time-dependent nature of the data; an analysis taking these into account (such as our direct
effects analysis) was required to determine if there was enough information in the MIRA
trial data to adjust for condom use and possibly uncover a positive effect of diaphragms.
Without such an analysis, readers of the Lancet article reporting only the MIRA trial
intention-to-treat results and differential condom use (Padian et al., 2007) may continue
to wonder whether there was evidence in the trial data for a benefit of the diaphragm
intervention.
We briefly discuss some alternative analyses that could be done to answer some im-
portant public health questions related to the MIRA trial. For example, one could try to
estimate diaphragm efficacy at a fixed level of condom use, that is, the effect of diaphragm
use D on HIV status I , fixing condom use C. We expect this would differ from what we
estimated using direct effects, which involved the effect of being assigned to the diaphragm
arm. An analysis of the effect of diaphragm use D on I , fixing condom use C would require
additional assumptions than our direct effects analysis, since one would have to deal with
time-dependent confounding of the effect of diaphragm use on HIV status. This highlights
an advantage of doing a direct effects analysis of treatment assignment in a randomized trial,
as we did in this paper: there cannot be confounders of (randomized) treatment assignment
and primary outcome.
Another type of causal analysis that could be applied to the MIRA trial is principal
stratification (Frangakis and Rubin, 2002). It could be used, for example to estimate the
effect of study arm assignment for just the group of women who would not have used
condoms regardless of which study arm they had been assigned to. This parameter may shed
light on the important public health question of whether a diaphragm intervention would
provide protection against HIV for women who cannot get their partners to consistently use
male condoms, or sustain high levels of condom use over time. A different set of assumptions
than for the direct effects analysis would be necessary to estimate this parameter (Frangakis
and Rubin, 2002); also, R cannot be assumed to be an instrumental variable, since R
potentially influences I through the separate causal pathway involving C.
The direct effects analysis can also be applied in trials with blinding, to try to remove
distortion caused by a secondary intervention given to both arms. For example, consider
microbicide trials in which a placebo (an inactive gel) is used, and participants cannot dis-
tinguish whether they are using the active microbicide or placebo, as discussed in Mantell
et al. (2005) and Trussell and Dominik (2005). In a truly blinded trial, assignment to differ-
ent study arms cannot affect the outcome through systematically modifying subjects’ risk
behaviours (such as condom use). But even in blinded trials, secondary interventions can
affect the intention-to-treat estimator, pushing it either toward or away from the efficacy
of the study product, as shown in Trussell and Dominik (2005). A direct effects analysis
can remove some of this distortion caused by a secondary intervention, if this secondary
intervention influences the outcome only through a measured, potentially controllable be-
haviour (e.g. condom use). A direct effects analysis produces an estimate of what the effect
of treatment assignment would have been, had subjects been constrained in this behaviour.
This information could be useful, for example, in a blinded microbicide trial with a strongly
positive intention-to-treat result; here, a direct effects analysis could try to uncover whether
intervention effectiveness might be very different in a setting without condom counselling in
which condom use were quite low. Similarly, in a blinded microbicide trial that resulted in
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a null intention-to-treat result, the direct effects analysis could elucidate whether condom
counselling could have pushed the intention-to-treat result far away from actual microbicide
efficacy.
Changes to the MIRA trial design could help alleviate some of the difficulties discussed
in this paper. For example, more resources could be put into recruiting participants whose
partners refuse to use condoms. This is the population for which the diaphragm intervention
was initially conceived, but in practice is difficult to recruit. Such a population would have
low condom use in both arms in the presence of intensive condom counselling, obviating
some of the problems discussed in this paper. To identify such subjects, recruiters could
screen for women having covariates that in the MIRA trial were highly predictive of low
condom use. There is much need for trial designs that are better able to target efficacy and
effectiveness of new HIV prevention methods.
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